TABLE 2.

Monthly costs of currently marketed QW GLP‐1 RAs

GLP‐1 RA	Maximum approved dose a	Median AWP (as of November 2019) 8 , b	Median NADAC (as of November 2019) 8 , b	Typical dosing schedule	Titration schedule
Dulaglutide 12	1.5 mg	USD 911	USD 730	Subcutaneous injection, QW	Initiate at 0.75 mg subcutaneously QW. Dose can be increased to 1.5 mg QW for additional glycaemic control
Exenatide ER 11	2 mg	USD 840	USD 672	Subcutaneous injection, QW	2 mg QW only
Semaglutide s.c. 10	1 mg	USD 927	USD 745	Subcutaneous injection, QW	Start at 0.25 mg QW. After 4 wk, increase the dose to 0.5 mg QW. If after at least 4 wk additional glycaemic control is needed, increase to 1 mg QW

Pricing data adapted from ADA Standards of Care 2020. ⁸

Abbreviations: ADA, American Diabetes Association; AWP, average wholesale price; ER, extended‐release; GLP‐1 RA, glucagon‐like peptide 1 receptor agonist; NADAC, National Average Drug Acquisition Cost; QW, once weekly; s.c., subcutaneous; wk, weeks.

^aUtilized to calculate median AWP and NADAC; generic prices used, if available commercially.

^bCalculated for 30‐d supply (AWP or NADAC unit price × number of doses required to provide maximum approved daily dose × 30 d); median AWP or NADAC listed alone when only one product and/or price.